The findings are consistent with prior research showing that counties lacking these services have poorer CV outcomes.

The device was not included as a potential treatment despite sham-controlled evidence showing it reduces patient symptoms.

With the pandemic having worsened burnout and intent to leave, the authors say keeping and supporting the workforce is ...

Sugar substitutes, substance abuse, GLP-1 drugs, and the biggest clinical trials of the year—each had their place in our top 10.

Newer therapies for multiple conditions were major stories this year, but long-term HF survival gains seem to have vanished.

Check out all our end-of-year content—the latest Heart Sounds podcast reviews the reporters’ own favorite stories for 2024, ...

Be it bullying, offensive language, or misuse of power, the cardiovascular community took a stand against disruptive behaviors this year, with some cardiovascular societies proactively issuing ...

For general cardiology and prevention, the year 2024 was all about novel treatments for new targets—be those lipoprotein(a), glucagon-like peptide-1 (GLP-1), or angiotensinogen. But at the same time, ...

Medicine is a balancing act, a mosaic of competing priorities. Just this week, I wrapped up a challenging coronary intervention and hurriedly planned a TAVR case before racing against the clock to ...